Dr. Minzhao Lin | Biochemistry | Best Researcher Award

Published on by Chemistry Awards

Dr. Minzhao Lin | Biochemistry | Best Researcher Award

Dr. Minzhao Lin , Biochemistry,  Lecturer at Dezhou University, China

Dr. Minzhao Lin is a dedicated biomedical researcher and currently serves as a Lecturer at Dezhou College, China. With a Ph.D. in Biology and Medicine from Sun Yat-sen University, he has established himself in the interdisciplinary fields of nanomedicine, cancer immunotherapy, and tumor microenvironment modulation. He has authored over 24 publications, with 7 as co-first or corresponding author, and actively contributed to national-level research projects focusing on advanced drug delivery systems. Skilled in nanocarrier design, cellular assays, animal modeling, and analytical techniques, Dr. Lin bridges materials science with biomedical innovation. As a project group administrator, he successfully oversaw key grant applications and cross-disciplinary collaborations. His research emphasizes innovation in cancer therapy using hierarchical and responsive nanoplatforms. Dr. Lin is passionate about translational medicine and continuously seeks to advance therapies that can impact clinical outcomes in oncology and beyond.

Professional Profile : 

Google Scholar

Orcid

Scopus 

Summary of Suitability for Award:

Dr. Minzhao Lin stands out as a strong candidate for the “Best Researcher Award” due to his outstanding interdisciplinary contributions to cancer nanomedicine and immunotherapy. With a Ph.D. from Sun Yat-sen University and over 24 peer-reviewed publications (7 as co-first/corresponding author), he has demonstrated deep expertise in designing stimuli-responsive nanocarriers, microneedle drug delivery systems, and immune-modulatory therapeutic platforms. His research addresses real-world biomedical challenges like tumor drug resistance and targeted delivery across the blood-brain barrier, which are of high clinical relevance. He has successfully co-led multiple nationally funded projects, managed high-level lab operations, and contributed to grant proposals, manuscript drafting, and final reporting—demonstrating leadership, innovation, and research management capabilities. His work is published in top-tier journals like Nature Communications, Biomaterials, and ACS Applied Materials & Interfaces—signaling international recognition and scholarly impact. Dr. Minzhao Lin exemplifies the criteria for the “Best Researcher Award”, given his innovative research, publication record, leadership in key national projects, and substantial contributions to translational cancer nanomedicine. His work is not only academically robust but also holds significant potential for clinical applications. He is highly deserving of this recognition.

🎓Education:

Minzhao Lin pursued his academic journey through prestigious Chinese institutions. He earned his Ph.D. in Biology and Medicine (2020–2024) from the College of Materials Science and Engineering at Sun Yat-sen University, Guangzhou, China. His doctoral work focused on hierarchical nanomedicine for cancer immunotherapy. Prior to that, he completed his M.Sc. in Plant Prevention and Biomaterials (2017–2020) at South China Agricultural University, where he built foundational expertise in biomaterials and pathogen defense. His undergraduate degree in Environmental Science (2013–2017), also from South China Agricultural University, was marked by outstanding academic performance, with a GPA of 4.15/5 and a rank of 5th out of 330 students. This diverse educational foundation in environmental science, biomaterials, and biomedicine has equipped Dr. Lin with a unique interdisciplinary perspective vital for innovation in nanomedicine and cancer research.

🏢Work Experience:

Dr. Minzhao Lin serves as a Lecturer at Dezhou College, where he engages in teaching and scientific research. During his doctoral studies at Sun Yat-sen University (2020–2024), he managed national research projects, coordinated multi-institutional collaborations, and played a central role in nanodrug development. As a Project Group Administrator, he handled proposal drafting, procurement, lab safety, and team management. His technical expertise encompasses synthesis of polymeric/lipid nanocarriers, in vitro/in vivo biological assessments, and advanced imaging and analysis. Dr. Lin has worked extensively on microneedle-based drug delivery systems for cancer immunotherapy and contributed significantly to the completion of NSFC and Guangzhou Municipal R&D projects. He has also published in high-impact journals and participated in project finalization and grant reporting. His scientific rigor and leadership skills make him a valuable contributor to biomedical innovation and higher education.

🏅Awards: 

Dr. Minzhao Lin has earned significant recognition for his contributions to biomedical research, particularly in the fields of nanomedicine and cancer immunotherapy. His scholarly impact is reflected in his role as co-first or corresponding author on seven high-impact publications and as co-author on an additional 17 papers in prestigious journals such as Nature Communications, Biomaterials, ACS Applied Materials & Interfaces, and Advanced Science. As a key contributor to two nationally funded research projects under the National Natural Science Foundation of China (NSFC) and the Guangzhou Municipal Key R&D Program, Dr. Lin successfully led the technical development and final reporting phases. His leadership as project group administrator resulted in the successful completion and approval of multiple major research grants. Through his innovative work on nanocarrier systems and microneedle-based delivery platforms, Dr. Lin has built a reputation for scientific excellence and research innovation, earning him institutional and collaborative accolades in China’s biomedical research community.

🔬Research Focus:

Minzhao Lin’s research centers on the development of hierarchical targeted nanomedicine for cancer immunotherapy . His work bridges materials science and oncology, designing multifunctional polymeric and lipid-based carriers that can modulate the tumor microenvironment, overcome drug resistance, and improve immune response activation. Key themes include ROS regulation, co-delivery of therapeutics, metabolism reprogramming, and stimuli-responsive systems. He has also advanced microneedle platforms and flocculant-based delivery technologies for therapeutic and environmental applications. Dr. Lin’s goal is to achieve precise and efficient drug delivery, especially in hard-to-treat cancers such as triple-negative breast cancer and glioma, through multimodal strategies. His collaborative efforts in integrating imaging, immunomodulation, and nanocarrier design reflect a holistic approach to personalized medicine and translational research.

Publication Top Notes:

1.Title: Surgical tumor-derived photothermal nanovaccine for personalized cancer therapy and prevention
Citations: 73

2.Title: GSH‐Responsive metal–organic framework for intratumoral release of NO and IDO inhibitor to enhance antitumor immunotherapy
Citations: 64

3.Title: Nanodrug augmenting antitumor immunity for enhanced TNBC therapy via pyroptosis and cGAS-STING activation
Citations: 56

4.Title: Floatable magnetic aerogel based on alkaline residue used for the convenient removal of heavy metals from wastewater
Citations: 41

5.Title: Transparent floatable magnetic alginate sphere used as photocatalysts carrier for improving photocatalytic efficiency and recycling convenience.
Citations: 34

6.Title: Nanodrug regulates lactic acid metabolism to reprogram the immunosuppressive tumor microenvironment for enhanced cancer immunotherapy
Citations: 33

7.Title: Nanodrugs incorporating LDHA siRNA inhibit M2-like polarization of TAMs and amplify autophagy to assist oxaliplatin chemotherapy against colorectal cancer
Citations: 26

8.Title: Tumor acidity-activatable macromolecule autophagy inhibitor and immune checkpoint blockade for robust treatment of prostate cancer
Citations: 23

9.Title: Retinol-binding protein-hijacking nanopolyplex delivering siRNA to cytoplasm of hepatic stellate cell for liver fibrosis alleviation
Citations: 23

10.Title: Nanodrug simultaneously regulates stromal extracellular matrix and glucose metabolism for effective immunotherapy against orthotopic pancreatic cancer
Citations: 23

 

Assist. Prof. Dr. Changtong YANG | Medicinal Chemistry | Best Researcher Award

Published on by Chemistry Awards

Assist. Prof. Dr. Changtong YANG | Medicinal Chemistry | Best Researcher Award

Assist. Prof. Dr. Changtong YANG , Medicinal Chemistry,  Radiochemist/Chemist at Singapore General Hospital, Singapore

Dr. Chang-Tong Yang is a renowned radiochemist based in Singapore, specializing in radiopharmaceuticals and molecular imaging. He currently serves as an Assistant Professor in the Radiological Science Academic Clinical Programme at Duke-NUS Medical School and as a Radiochemist at Singapore General Hospital. With over two decades of experience, Dr. Yang has made significant contributions to the development of nuclear imaging probes and radiolabeled therapeutics. His research career spans prestigious institutions, including Nanyang Technological University and A*STAR. Dr. Yang is internationally recognized for advancing nanomaterial probes and novel radiolabeling strategies. He has authored impactful publications in top-tier journals, reflecting his innovation in theranostics, radiochemistry, and nanomedicine. With a strong background in academic and clinical research, Dr. Yang continues to shape the future of molecular imaging for personalized medicine. His global education and interdisciplinary expertise make him a leading figure in translational radiochemistry research.

Professional Profile : 

Orcid

Scopus 

Summary of Suitability for Award:

Dr. Chang-Tong Yang exemplifies the qualities of a “Best Researcher Award” recipient. His innovative contributions to radiochemistry and molecular imaging, combined with a strong publication record, interdisciplinary leadership, and global training, establish him as a trailblazer in translational medical research. His work is not only scientifically rigorous but also clinically impactful, directly advancing the field of nuclear medicine. Therefore, he is highly recommended for recognition as a top-tier researcher deserving of this award.

🎓Education:

Dr. Chang-Tong Yang received his Ph.D. in Chemistry from the National University of Singapore (1998–2002), where he laid the foundation for his career in radiochemistry. He further enhanced his expertise with postdoctoral fellowships at three prestigious U.S. institutions: University of Iowa (2003–2005), University of Michigan (2005–2006), and Purdue University (2006–2007), focusing on chemistry and health sciences. These formative years provided Dr. Yang with a multidisciplinary perspective in synthetic chemistry, radiopharmaceutical development, and imaging sciences. His international training exposed him to cutting-edge methodologies and collaborative projects across biomedical research, which he has since translated into innovative imaging solutions. The combination of rigorous education and hands-on research across these top institutions shaped his ability to bridge fundamental science with clinical applications, particularly in nuclear medicine and molecular imaging.

🏢Work Experience:

Dr. Chang-Tong Yang brings extensive professional experience across both academic and clinical research settings. He is currently an Assistant Professor at Duke-NUS Medical School (2020–present) under the Radiological Science ACP, focusing on radiopharmaceutical sciences. Concurrently, he serves as a Radiochemist at Singapore General Hospital (2018–present) in the Department of Nuclear Medicine & Molecular Imaging, where he translates research into clinical practice. Prior to that, he worked as a Senior Scientist at Nanyang Technological University (2014–2018), contributing to molecular imaging initiatives within the Lee Kong Chian School of Medicine. He also held a Senior Scientist role at A*STAR’s Singapore Bio-Imaging Consortium (2007–2014), leading various radiochemistry research programs. Across these roles, Dr. Yang has developed and validated imaging agents, optimized radiolabeling techniques, and led translational studies that impact diagnostic imaging and therapeutic strategies. His multidisciplinary engagements underscore his pivotal role in bridging chemistry and medicine.

🏅Awards: 

While specific awards are not listed in the available data, Dr. Chang-Tong Yang’s extensive contributions to radiopharmaceuticals and molecular imaging reflect a highly respected and impactful career. His appointments at top institutions such as Duke-NUS, A*STAR, and Singapore General Hospital indicate peer recognition and institutional trust. His publications in reputed journals such as Molecules, Nanomaterials, and Drug Discovery Today highlight his standing in the scientific community. His ongoing leadership roles and collaboration with clinicians further underscore professional acknowledgment of his expertise. Dr. Yang’s selection for multiple postdoctoral positions at prestigious U.S. institutions—University of Iowa, University of Michigan, and Purdue University—suggests early recognition of his academic promise. His interdisciplinary contributions to nuclear medicine, nanotechnology, and molecular imaging may have earned him internal institutional awards, research grants, and invitations to present at scientific forums, which commonly accompany such roles.

🔬Research Focus:

Dr. Chang-Tong Yang’s research is centered on radiopharmaceutical science, with a strong emphasis on the development of molecular imaging probes and radiolabeled nanomaterials for diagnostic and therapeutic applications. His expertise lies in designing novel radioisotope-labeled compounds for use in nuclear medicine imaging techniques such as PET and SPECT, targeting cancer and other pathological conditions. He is particularly interested in enhancing the in vivo behavior of nanomaterial-based agents, improving tumor targeting, retention, and safety. Dr. Yang also explores the biocompatibility and stability of these probes, including how formulation and labeling protocols influence their function. His translational work bridges laboratory innovations with clinical imaging requirements, enabling personalized diagnostics and theranostic approaches. Furthermore, he investigates radiochemical compatibility in clinical settings, such as the mixing of imaging agents with contrast media, which supports safe and effective imaging protocols. His work integrates chemistry, imaging, and clinical practice seamlessly.

Publication Top Notes:

1. pH-Induced In Situ Aggregation of Cu₂₋ₓSe-POED with Extended Tumor Retention for Enhanced Chemodynamic/Photothermal Therapy

2. Standard Radio-Iodine Labeling Protocols Impaired the Functional Integrity of Mesenchymal Stem/Stromal Cell Exosomes

3. Radiolabeled Liposomes for Nuclear Imaging Probes

4. Radiochemical Feasibility of Mixing of 99mTc-MAA and 90Y-Microspheres with Omnipaque Contrast

5. Nanomaterial Probes for Nuclear Imaging

6. Positron Emission Tomographic Imaging in Drug Discovery

7. An In Vivo Study of a Rat Fluid-Percussion-Induced Traumatic Brain Injury Model with [11C]PBR28 and [18F]flumazenil PET Imaging

8. Gadolinium-Based Bimodal Probes to Enhance T1-Weighted Magnetic Resonance/Optical Imaging

9. Activatable Cell-Penetrating Peptide Conjugated Polymeric Nanoparticles with Gd-Chelation and Aggregation-Induced Emission for Bimodal MR and Fluorescence Imaging of Tumors

10. Dealing with PET Radiometabolites

11. PET-MR and SPECT-MR Multimodality Probes

 

Assoc. Prof. Dr. Ningbo Li | Medicinal Chemistry | Best Researcher Award

Published on by Chemistry Awards

Assoc. Prof. Dr. Ningbo Li | Medicinal Chemistry | Best Researcher Award

Assoc. Prof. Dr. Ningbo Li , Medicinal Chemistry , Shanxi Medical University, China

Dr. Ningbo Li is an accomplished Associate Professor at the School of Basic Medical Sciences, Shanxi Medical University, with a strong academic foundation and a passion for cancer research. With a doctorate in Organic Chemistry from Hunan University, Dr. Li has built a reputable career in green synthesis, targeted nano-drug delivery systems, and near-infrared fluorescent probes molecule for cancer diagnostics and therapy. He has led over 10 national and provincial research projects, published 46 SCI-indexed papers, and holds 5 authorized patents. Dr. Li also contributes to academia through textbooks and serves as a Young Editorial Board Member of Journal of Xiangtan University. His collaborations span leading institutions like Hunan University and Nankai University. With 863 citations and rising influence, Dr. Li is committed to pioneering innovative, low-toxicity cancer therapeutics and translating lab findings into clinical advances.

Professional Profile : 

Orcid   

Scopus 

Summary of Suitability for Award:

Dr. Ningbo Li, Associate Professor at Shanxi Medical University, has demonstrated exceptional research productivity and innovation in the fields of organic chemistry, nanomedicine, and cancer therapeutics. With over 50 SCI-indexed publications, 5 authorized patents, and leadership on more than 10 national and provincial-level research projects, Dr. Li has made significant contributions to targeted cancer treatment and green synthesis of anti-tumor agents. His pioneering work on magnetic nano-drug delivery systems and near-infrared fluorescent probes molecule showcases translational potential for clinical applications in oncology. Furthermore, his involvement in academic book publications, editorial duties, and inter-institutional collaborations reflects both leadership and scholarly impact. With a citation index of 863 and consistent innovation through funded research, Dr. Li exemplifies the qualities of a top-tier researcher. Dr. Ningbo Li is highly suitable for the “Best Researcher Award”, as he meets and exceeds the criteria in terms of research excellence, innovation, scientific impact, and societal relevance. His dedication to advancing cancer research through interdisciplinary chemistry and his strong track record in publications, patents, and funded projects make him a deserving and outstanding candidate for this prestigious recognition

🎓Education:

Dr. Ningbo Li’s academic journey began with a Bachelor’s degree in Chemistry from Shanxi Datong University (2005–2009). He pursued his postgraduate studies at Hunan University, earning a Master’s degree (2009–2012) and subsequently a Ph.D. in Organic Chemistry (2012–2015). His academic training emphasized organometallic chemistry, chiral complex synthesis, and catalysis, laying the groundwork for his future research in drug development and nanomedicine. During his doctoral studies, Dr. Li specialized in chiral Lewis acids, exploring their role in asymmetric synthesis—an area critical to pharmaceutical innovation. His graduate work was pivotal in shaping his later focus on bio-compatible metal complexes and tumor-targeted drug delivery platforms. The integration of organic synthesis with biomedical applications became a hallmark of his educational path, culminating in a multidisciplinary approach that bridges chemistry, nanotechnology, and medical science.

🏢Work Experience:

Dr. Ningbo Li began his academic career as a Lecturer (2015–2018) at the School of Basic Medical Sciences, Shanxi Medical University, where he conducted interdisciplinary research and mentored students. In December 2018, he was promoted to Associate Professor, reflecting his growing contributions to research and teaching. With over a decade in academia, he has supervised numerous graduate projects and continues to develop innovative strategies for targeted cancer therapy using nanomaterials and fluorescent probes. Dr. Li has consistently received competitive research funding from the National Natural Science Foundation of China and the Shanxi Provincial Science Foundations. He also actively contributes to national teaching excellence through authorship in leading organic chemistry textbooks. His dedication to both scientific advancement and student development underscores a career that blends high-impact research with academic leadership in medical and chemical sciences.

🏅Awards: 

While specific named awards are not detailed, Dr. Ningbo Li’s academic honors are evident through his prestigious research grants, editorial board appointment, and book contributions. He is the Principal Investigator for multiple national-level research projects, including NSFC Young Scholar Awards, which are highly competitive and indicative of early-career excellence. His appointment as a Young Editorial Board Member of the Journal of Xiangtan University (Natural Science Edition) further reflects his scientific influence and peer recognition. Dr. Li’s patents on chiral zirconium and titanium complexes also highlight his innovative contributions to chemical synthesis. Moreover, his extensive publishing record and the high citation index (863) attest to the impact of his research in organic and medicinal chemistry. Through his involvement in writing authoritative textbooks used in higher education, Dr. Li has contributed significantly to the academic development of students and educators in China.

🔬Research Focus:

Dr. Ningbo Li’s research is centered on the interdisciplinary interface of organic chemistry, nanotechnology, and cancer therapeutics, with a strong emphasis on green and sustainable chemistry. His primary focus lies in the design and synthesis of functionalized magnetic nanocomposites and near-infrared fluorescent probe molecules for the precise diagnosis and targeted treatment of malignant tumors. By engineering magnetic-targeted nano-drug delivery systems, his team aims to achieve site-specific drug accumulation, minimizing systemic toxicity and enhancing therapeutic efficacy. Another key area involves the green synthesis of novel bioactive compounds, particularly chiral organometallic complexes, which exhibit promising anti-tumor properties. His group also explores chiral Lewis acids as catalysts in asymmetric reactions, crucial for the development of structurally complex pharmaceuticals. Dr. Li’s research is highly translational, striving to bridge the gap between bench and bedside by accelerating the clinical application of biocompatible, efficient, and low-toxicity cancer therapeutics rooted in advanced chemical innovation.

Publication Top Notes:

1. g-C₃N₄-Based Heterogeneous Photocatalyzed Synthesis and Evaluation of Antitumor Activities of Fluoroalkylated 4H-Pyrido[1,2-a]pyrimidin-4-ones

2. Magnetic Nanocarriers for pH/GSH/NIR Triple-Responsive Drug Release and Synergistic Therapy in Tumor Cells

3. GSH-Responsive Magnetic Mesoporous Silica Nanoparticles for Efficient Controlled Drug Delivery in Tumor Cells

 

​

Prof. Dr. Pengwei Zhao | Medicinal Chemistry | Best Researcher Award

Published on by Chemistry Awards

Prof. Dr. Pengwei Zhao | Medicinal Chemistry | Best Researcher Award

Prof. Dr. Pengwei Zhao | Medicinal Chemistry | Ph.D., Master’s Supervisor at Inner Mongolia Medical University, School of Basic Medical Sciences, China 

Dr. Pengwei Zhao is a Professor at the School of Basic Medical Sciences, Inner Mongolia Medical University, he serves as a master’s supervisor and holds various academic positions. He is a member of the Jiusan Society and actively contributes to scientific research as a registered reviewer for Medical Science Monitor and Chinese Journal of Tissue Engineering Research. He is also a youth editorial board member of Modern Oncology and a director of the Inner Mongolia Bioengineering Society. His research focuses on tumor immunology and pharmacological mechanisms of Mongolian medicine. Dr. Zhao has led multiple national and regional research projects, including studies on β-defensins, immune resistance, and cancer treatment mechanisms. His contributions to microbiology and oncology are widely recognized, with several impactful publications in international journals.

Professional Profile : 

Orcid

Scopus 

Summary of Suitability for Award:

Dr. Pengwei Zhao, a distinguished Professor at Inner Mongolia Medical University, has made significant contributions to tumor immunology, cancer pharmacology, and Mongolian medicine. His research on β-defensins and their role in immune modulation and cancer therapy has led to groundbreaking findings, particularly in colorectal and triple-negative breast cancer (TNBC). With numerous high-impact publications, including in Pharmacogenomics Journal and World Journal of Gastrointestinal Oncology, his work is recognized globally. His ongoing National Natural Science Foundation of China project further highlights his leadership in cancer research.  Dr. Pengwei Zhao’s extensive research, innovative methodologies, and interdisciplinary approach make him an outstanding candidate for the “Best Researcher Award”. His contributions to immunotherapy, autophagy, and microbiome-related cancer treatments have the potential to shape future oncological therapies. Recognizing him with this award would honor his pioneering discoveries and impact on global cancer research.

🎓Education:

Dr. Pengwei Zhao holds a Ph.D. in Basic Medical Sciences with a specialization in tumor immunology and pharmacology. His doctoral research focused on β-defensin-mediated immune modulation and cancer therapy. He pursued his higher education at Inner Mongolia Medical University, where he developed expertise in molecular biology, pharmacology, and immunology. His early education emphasized microbiology and traditional Mongolian medicine. Dr. Zhao further enhanced his skills through postdoctoral research and collaborations with leading scientists in cancer biology. His education provided a strong foundation in oncological pharmacology, signaling pathways, and immune resistance mechanisms. He has continuously expanded his knowledge through national and international conferences, workshops, and training programs. His academic journey reflects a commitment to translational research, bridging basic science with clinical applications in cancer therapy.

🏢Work Experience:

Dr. Zhao has been a Professor at Inner Mongolia Medical University for several years, where he also serves as a Master’s Supervisor. His professional roles extend beyond teaching, as he holds multiple directorial positions in national and regional scientific societies. He is a reviewer for prestigious journals, including Medical Science Monitor and Chinese Journal of Digestive Diseases. As a youth editorial board member of Modern Oncology, he actively contributes to cancer research. He has successfully led multiple research projects funded by national and regional agencies, focusing on cancer immunology, microbiology, and Mongolian medicine-based therapies. Additionally, Dr. Zhao has conducted collaborative research on β-defensins, autophagy, and immune resistance mechanisms. His expertise in pharmacological pathways and microbial interactions has significantly advanced the understanding of cancer treatment. He has also been invited as a speaker and panelist at various oncology and pharmacology conferences.

🏅Awards: 

Dr. Pengwei Zhao has received multiple prestigious awards and honors in recognition of his contributions to tumor immunology and Mongolian medicine research. He has been honored by the Inner Mongolia Medical University for excellence in research and mentorship. His work on β-defensins and their role in cancer has earned him accolades from Inner Mongolia’s Science and Technology Department. He has also received distinguished reviewer awards from journals such as Medical Science Monitor and Chinese Journal of Tissue Engineering Research. As a key member of the Chinese Society of Ethnomedicine and Pharmacy, he has been acknowledged for his research on the pharmacological mechanisms of traditional Mongolian medicine. His contributions to microbiology and immunology have been recognized by the Inner Mongolia Microbiology Society, and he has been invited as a young committee member of the Chinese Microbiological Society’s Clinical Microbiology Professional Committee.

🔬Research Focus:

Dr. Pengwei Zhao’s research primarily focuses on tumor immunology, cancer pharmacology, and the therapeutic potential of Mongolian medicine. He investigates the molecular mechanisms of β-defensins in cancer, particularly their role in immune regulation and tumor suppression. His work explores how β-defensin-1 peptides modulate PD-1/PD-L1 immune resistance in colorectal cancer. Additionally, he studies Mongolian medicinal formulations like Sendeng-4 and their mechanisms against skin cancer. His research also extends to microbiology, analyzing how bacterial infections, such as those caused by Staphylococcus aureus and Klebsiella pneumoniae, influence lung epithelial immune responses. Dr. Zhao has also contributed significantly to understanding long noncoding RNAs (lncRNAs) and their regulatory impact on autophagy pathways in cancer. His interdisciplinary approach integrates immunology, molecular biology, and ethnopharmacology, providing novel insights into cancer therapy, host-pathogen interactions, and the development of targeted immunotherapies.

Publication Top Notes:

Upregulation of p300 in paclitaxel-resistant TNBC: implications for cell proliferation via the PCK1/AMPK axis

Authors: P. Zhao, Pengwei; J. Cui, Jiaxian; X. Wang, Xiumei

Journal: Pharmacogenomics Journal

Year: 2024

Citations: 2

Human β-defensin-1 affects the mammalian target of rapamycin pathway and autophagy in colon cancer cells through long non-coding RNA TCONS_00014506

Authors: Y. Zhao, Yuxin; Y. Cui, Yan; X. Li, Xinhong; L. Bao, Lili; P. Zhao, Pengwei

Journal: World Journal of Gastrointestinal Oncology

Year: 2024

Citations: 3

Effect of Staphylococcus aureus in pneumonia mouse model on promotion of mBD-3 expression through ERK1/2

Authors: Yongqing Ni, Xiaoduo Bi, Pengwei Zhao

Ligilactobacillus salivarius LZZAY01 accelerated autophagy and apoptosis in colon cancer cells and improved gut microbiota in CAC mice

Authors: Yang W, Li T, An S, Chen R, Zhao Y, Cui J, Zhang M, Lu J, Tian Y, Bao L, Zhao P

Journal: Microbiol Spectrum

Year: 2025

LPS Promoted HPMEC Autophagy by Suppression of the PI3K/Akt/mTOR through Inhibited TIMAP-Promoted Moesin Expression in Sepsis

Authors: Jili Wen, Pengwei Zhao, HuiJuan Ren, JunMin Wu

Journal: Journal of Biological Regulators and Homeostatic Agents

Year: 2023